BioSpace News Archive

Savings from just four of 10 drugs covered by the Inflation Reduction Act’s Drug Negotiation Program could reach $1.8 billion during the first year of implementation, according to research.

The regulator Wednesday approved expanding Lonsurf’s label for previously treated metastatic colorectal cancer, authorizing a combination regimen with Roche’s bevacizumab.

The biotech Thursday reported that second-quarter sales of its COVID shot dropped 94%. However, it expects $6 billion to $8 billion in revenue this year, up from a previous forecast of $5 billion.

During Regeneron’s second-quarter earnings call Thursday, the company said that the regulator could make its decision on 8-mg Eylea in the third quarter—much earlier than market expectations.

MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis ® Fast-Dissolve Technology for Use with MM-120.

Axcella Therapeutics today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Kane Biotech Inc. announces its intention to undertake a non-brokered private placement offering of up to 6,250,000 units of the Company at a price of $0.08 per Unit for gross proceeds of up to $500,000.

Predictive Oncology Inc. today announced that it will report its financial results for the second quarter ended June 30, 2023 after the markets close on Thursday, August 10, 2023.

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Humacyte, Inc. announces the publication of controlled in vitro studies in the Journal of Vascular Surgery – Vascular Science describing the scientific basis for the significantly lower rates of infection observed in a clinical trial of the investigational HAV compared to synthetic expanded polytetrafluoroethylene grafts.